Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Holmes S, Rudnicka L, Blauvelt A, Zlotogorski A, Candiani JO, Edwards RA, Sadrarhami MM, Wolk R, Tran H September 10, 2022 EADV 2022 Alopecia

Association Between Early Eyebrow/Eyelash Assessments and Subsequent Scalp Hair Regrowth in Patients With Alopecia Areata Treated With Ritlecitinib: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

View Presentation
Poster
Zhang X, Magnolo N, Mizuashi M, Mesinkovska N, Shapiro J, Zhang F, Kerkmann U, Law E, Wolk R, Schaefer G September 10, 2022 EADV 2022 Alopecia

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

View Presentation
Poster
Blume-Peytavi U, Harcha JWG, Yang Q, Schmieder GJ, Hordinsky MK, Micali G, Ohyama M, Takiya L, Zhang F, Schaefer G, Wolk R, Kerkmann U September 10, 2022 EADV 2022 Alopecia

Evaluation of Response to Ritlecitinib (PF-06651600) Treatment Based on SALT Improvement Scores in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

View Presentation
Poster
King B, Bergfeld W, Brzewski P, Aşkin Ö, Passeron T, Randhawa S, Law E, Edwards RA, Wolk R, Zwillich SH, Lejeune A September 10, 2022 EADV 2022 Alopecia

Impact of disease history on the efficacy of ritlecitinib (PF-06651600) in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

View Presentation
Poster
Anderson P, Marwaha S, Piercy J, Law EH, Wolk R, Schaefer G, Neary MP September 10, 2022 EADV 2022 Alopecia

Impact of Scalp Hair Loss on Treatment Patterns and Physician Satisfaction with Disease Control for Alopecia Areata Patients in Europe

View Presentation
Poster
Law E, Sherif B, Williams N, Mitra D, Neary M, Nelson L, Harries M September 10, 2022 EADV 2022 Alopecia

Improvements in Patient-Reported Outcomes Based on Scalp Hair Regrowth Among Patients With Alopecia Areata: Analysis of the ALLEGRO 2b/3 Trial

View Presentation
Oral Presentation
Sinclair R, Lesiak A, Mehlis S, Kinoshita-Ise M, Arenberger P, Tsianakas A, Tziotzios C, Zhang F, Law EH, Lejeune A, Wolk R, Woodworth D September 10, 2022 EADV 2022 Alopecia

Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata: interim results from the ALLEGRO-LT phase 3, open-label study

View Presentation
Poster
Jennifer Soung, Brett King, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rie Ueki, Rodney Sinclair, Fan Zhang, Helen Tran, Robert Wolk March 21, 2023 AAD 2023 Alopecia

Integrated safety analysis of ritlecitinib in adolescent patients with alopecia areata from the randomized, placebo-controlled ALLEGRO phase 2b/3 and ongoing open-label phase 3 ALLEGRO-LT studies

View Presentation
Poster
Maryanne Senna, Seth Forman, Lindsey Bordone, Pablo De La Cueva Dobao, Robert Wolk, Samuel H. Zwillich, Fan Zhang, Haytham Mohamed Ahmed, Liza Takiya March 21, 2023 AAD 2023 Alopecia

Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study

View Presentation
Oral Presentation
Melissa Piliang, Charles Lynde, Brett King, Paradi Mirmirani, Rodney Sinclair, Robert Wolk, Samuel H. Zwillich, Helen Tran, Fan Zhang, Liza Takiya March 21, 2023 AAD 2023 Alopecia

Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

View Presentation